Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhan, Na ^a,b   Xiu, Bing S ^a   Wang, Guo H ^a   Chen, Kun ^a   Bai, Guan Z ^a   Song, Xiao G ^a   Zhu, Cui X ^a   Dai, Zhen H ^a   Yang, Xi Q ^a   Zhang, He Q ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Beijing 307 Hospital   (China)

Author keywords

adjuvant; ELISPOT; FCM; HCV; humoral immunity

Indexed keywords

ALUMINUM; ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; HVR1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 6; PHOSPHATE BUFFERED SALINE; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELL COUNT; CONTROLLED STUDY; CROSS REACTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PLASMA CELL; SPLEEN LYMPHOCYTE; TH2 CELL; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY-PRODUCING CELLS; ANTIGENS, CD; ENZYME-LINKED IMMUNOSPOT ASSAY; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTES; MICE; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; RABBITS; SPLEEN; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS;

HEPATITIS C VIRUS; MUS; ORYCTOLAGUS CUNICULUS;

EID: 80355131482     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-507     Document Type: Article

References (39)

1. Global epidemiology of hepatitis C virus infection. Shepard CW, Finelli L, Alter M, Lancet Infect Dis 2005 5 558 567 10.1016/S1473-3099(05)70216-4 16122679 (Pubitemid 41196755)
2. Immunology of hepatitis B virus and hepatitis C virus infection. Rehermann B, Nascimbeni M, Nat Immunol 2005 5 215 229 10.1038/nri1573 (Pubitemid 40364823)
3. Flying under the radar: the immunobiology of hepatitis C. Dustin LB, Rice CM, Annu Rev Immunol 2007 25 71 99 10.1146/annurev.immunol.25.022106.141602 17067278 (Pubitemid 46697903)
4. Study on the complex hepatitis C virus antigen with multi-genotype E1 epitopes. He F, Tang L, Wang GH, Zhang HQ, Chen K, Zhu CX, Chin J Micmhiol Immunol 2009 29 1 46 52
5. Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus. Xiu BS, Ling SG, Song XG, Zhang HQ, Chen K, Zhu CX, World J Gastro 2003 9 6 1256 60 (Pubitemid 36805663)
6. Adjuvants - essential components of new generation vaccines. Dzierzbicka K, Koodziejczyk AM, Postepy Biochem 2006 52 2 204 11 17078510
7. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Gupta K, Cooper C, Drugs R D 2008 9 3 137 45 10.2165/00126839- 200809030-00001 18457466 (Pubitemid 351651997)
8. Plasmacytoid dendritic cell precursorstype I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Ito T, Wang YH, Liu YJ, Springer Semin Immunopathol 2005 26 221 229 10.1007/s00281-004-0180-4 15592841
9. Innate immune recognition of viral infection. Kawai T, Akira S, Nat Immunol 2006 7 2 131 137 16424890 (Pubitemid 43135878)
10. CpG Inhibits Pro-B Cell Expansion through a Cathepsin B-Dependent Mechanism. Lalanne AI, Moraga I, Hao Y, Pereira JP, Alves NL, Huntington ND, Freitas AA, Cumano A, Vieira P, J of Immunol 2010 184 5678 5685 10.4049/jimmunol.0903854
11. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Vollmer J, Expert opin biol Thera 2005 5 673 682 10.1517/14712598.5.5.673 (Pubitemid 40780550)
12. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. Hoshino K, Takeuchi T, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S, J Immunol 1999 162 3749 3752 10201887 (Pubitemid 29314747)
13. CpG motifs in bacterial DNA trigger direct B-cell activation. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM, Nature 1995 374 546 549 10.1038/374546a0 7700380
14. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Alexopoulou L, Holt AC, Medzhitov R, et al. Nature 2001 413 732 738 10.1038/35099560 11607032 (Pubitemid 33009951)
15. Recognition of single stranded RNA viruses by Toll-like receptor 7. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA, Proc Nat Acad Sci 2004 101 5598 5603 10.1073/pnas.0400937101 15034168 (Pubitemid 38481202)
16. Adjuvant properties of aluminum and calcium compounds. Gupta RK, Rost BE, Relyveld E, et al. Pharm Biotechnol 1995 6 229 248 7551219
17. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. François V, Roger B, Claire MH, et al. Vaccine 2005 23 11 1359 1367 10.1016/j.vaccine.2004.09.012 15661384 (Pubitemid 40127328)
18. In interleukin-4-deficient mice alum not only generates T helper l responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Brewer JM, Conacher M, Satoskar A, et al. Eur J lmmunol 1996 26 9 2062 2066 10.1002/eji.1830260915 (Pubitemid 26297502)
19. Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Joseph VR, White JL, Stanley LH, Vaccine 1996 14 4 298 300 10.1016/0264-410X(95)00194-6 8744556 (Pubitemid 26127812)
20. Aluminum compounds used as adjuvants in vaccines. Shirodkar S, Hutchinson RL, Perry DL, et al. Pharm Res 1990 7 282 1288
21. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Stephanie MN, Mark AG, Harm HE, et al. Vaccine 2010 28 3588 3594 10.1016/j.vaccine.2010.02.085 20211692
22. B cells as effectors. McHeyzer-Williams MG, Curr Opin Immunol 2003 15 354 361 10.1016/S0952-7915(03)00046-3 12787764 (Pubitemid 36645115)
23. Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early Activation of p38 MAPK. Ertesvag A, Aasheim HC, Naderi S, et al. Blood 2007 109 9 3865 3872 10.1182/blood-2006-09- 046748 17209053 (Pubitemid 46641738)
24. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Bernasconi NL, Onai N, Lanzavecchia A, et al. Blood 2003 101 4500 4504 10.1182/blood-2002-11-3569 12560217 (Pubitemid 36857820)
25. Antibody Production and In Vitro Behavior of CD27-Defined B-Cell Subsets: Persistent Hepatitis C Virus Infection Changes the Rules. Vito R, Maria AF, Patrizia L, et al. J of Viro 2006 4 80 3923 3934
26. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Shinichi S, Paul JJ, Thomas FT, Proc Nat Acad Sci 1997 94 13158 13162 10.1073/pnas.94.24.13158 9371816 (Pubitemid 27518492)
27. Characteristics of early murine B-lymphocyte precursors and their direct sensitivity to negative regulators. Taku K, Kay LM, Kenji O, et al. Blood 2001 97 9 2708 2715 10.1182/blood.V97.9.2708 11313262
28. A B lymphocyte surface molecule mediating activation and protection from apoptosis via calcium channels. Santos AL, Teixeira C, Preece G, et al. J Immunol 1993 151 3119 3130 8397252 (Pubitemid 23282623)
29. Expression cloning of a cDNA encoding a novel murine B cell activation marker. Harada N, J Immunol 1993 151 3111 3118 8376770 (Pubitemid 23282622)
30. CpG DNA activation and plasma-cell differentiation of CD27- nave human B cells. Jennifer H, Tina P, Raymond E, et al. Blood 2007 109 4 1611 1619 10.1182/blood-2006-03-008441 17032927 (Pubitemid 46239595)
31. Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. Lund FE, Yu N, Kim KM, et al. J Immunol 1996 157 4 1455 1467 8759726 (Pubitemid 126449083)
32. IgG1 production by sIgD+ splenic B cells and peritoneal B-1 cells in response to IL-5 and CD38 ligation. Yasue T, Baba M, Mori S, et al. Int Immunol 1999 11 6 915 923 10.1093/intimm/11.6.915 10360965 (Pubitemid 29276603)
33. Signaling Properties of CD38 in the Mouse Immune System: Enzyme-dependent and -independent Roles in Immunity. Frances EL, Lund 2006 12 11-12 328 333
34. Maintenance of serological memory by polyclonal activation of human memory B cells. Bernasconi NL, Traggiai E, Lanzavecchia A, et al. Science 2002 298 2199 2202 10.1126/science.1076071 12481138 (Pubitemid 35471246)
35. Modulation of Single-Cell IgG Secretion Frequency and Rates in Human Memory B Cells by CpG DNA, CD40L, IL-21, and Cell Division. Henn AD, Rebhahn J, Brown MA, et al. J of Immunol 2009 183 3177 3187 10.4049/jimmunol.0804233
36. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. Yu H, Babiuk LA, Hurk S, et al. J Gen Virol 2004 85 1533 1543 10.1099/vir.0.79821-0 15166437 (Pubitemid 38807750)
37. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by codelivery of protein antigen and CpG with cationic liposomes. Jiao X, Yan-Hui Wang R, Qiu Q, et al. J Gen Virol 2004 85 1545 1553 10.1099/vir.0.79896-0 15166438 (Pubitemid 38807751)
38. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Weeratna RD, McCluskie MJ, Xu Y, et al. Vaccine 2000 18 17 1755 1762 10.1016/S0264-410X(99)00526-5 10699323 (Pubitemid 30122837)
39. pUCpGs10 increases vaccine antigen-specific cell-mediated immunitywhen administered with hepatitis B vaccine in HIV infection. Angel JB, Cooper CL, Clinch J, et al. J Immu Bas Thera Vac 2008 6 4 1 7